Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Ann Romney Center for Neurologic Disease, Harvard Medical School, Boston, Massachusetts, USA.
Expert Rev Neurother. 2020 May;20(5):509-516. doi: 10.1080/14737175.2020.1757434. Epub 2020 Apr 26.
: Recent research has shown that IL-6 receptor (IL-6 R) inhibitors like tocilizumab and satralizumab are effective in reducing the relapse rate in patients with NMOSD.: This review article explores current concepts in NMOSD management and focuses on IL-6 R as a therapeutic target. The authors delve into the biological and immunological role of IL-6 in the pathogenesis of NMOSD. Further, the authors summarize the most recent findings on the use of anti-IL-6 R monoclonal antibodies, tocilizumab and satralizumab, in the treatment of NMOSD.: A better understanding of the role of cytokines in NMOSD may provide the neurologist with novel therapies for this disease. IL-6 R appears to be a central hub to NMOSD pathogenesis and a relevant therapeutic target.
: 最近的研究表明，白细胞介素 6 受体（IL-6R）抑制剂，如托珠单抗和萨替利珠单抗，可有效降低 NMOSD 患者的复发率。这篇综述文章探讨了 NMOSD 管理的当前概念，并侧重于 IL-6R 作为治疗靶点。作者深入研究了白细胞介素 6 在 NMOSD 发病机制中的生物学和免疫学作用。此外，作者总结了最近关于抗白细胞介素 6R 单克隆抗体，托珠单抗和萨替利珠单抗，在 NMOSD 治疗中的应用的研究结果。更好地了解细胞因子在 NMOSD 中的作用可能为神经病学家提供针对这种疾病的新疗法。IL-6R 似乎是 NMOSD 发病机制的中心枢纽，也是一个相关的治疗靶点。
